Bayer AG (BAYN) Receives Average Recommendation of “Buy” from Brokerages
Shares of Bayer AG (FRA:BAYN) have been assigned a consensus rating of “Buy” from the twenty-two ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is €123.00 ($146.43).
A number of research analysts recently issued reports on the stock. Independent Research set a €120.00 ($142.86) target price on shares of Bayer and gave the company a “neutral” rating in a research report on Friday. Citigroup reiterated a “buy” rating on shares of Bayer in a research report on Thursday. Warburg Research set a €121.00 ($144.05) target price on shares of Bayer and gave the company a “neutral” rating in a research report on Thursday. JPMorgan Chase & Co. set a €128.00 ($152.38) target price on shares of Bayer and gave the company a “buy” rating in a research report on Wednesday. Finally, Commerzbank set a €124.00 ($147.62) target price on shares of Bayer and gave the company a “buy” rating in a research report on Friday, October 6th.
Shares of Bayer (FRA BAYN) traded down €0.62 ($0.74) during midday trading on Tuesday, hitting €104.86 ($124.83). 2,223,938 shares of the stock were exchanged. Bayer has a 1 year low of €99.69 ($118.68) and a 1 year high of €123.82 ($147.40). The firm has a market cap of $86,730.00 and a P/E ratio of 28.11.
ILLEGAL ACTIVITY NOTICE: “Bayer AG (BAYN) Receives Average Recommendation of “Buy” from Brokerages” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://theolympiareport.com/2018/01/14/bayer-ag-bayn-receives-average-recommendation-of-buy-from-brokerages.html.
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.